<DOC>
	<DOCNO>NCT02380274</DOCNO>
	<brief_summary>The purpose study describe pattern care CRPC patient , well health-related quality life ( HRQoL ) outcomes associate CRPC management . This study also describe factor influence treatment decision include reason ( ) treatment choice trigger treatment change CRPC well describe clinical outcome base patient characteristic .</brief_summary>
	<brief_title>Observational Cohort Study Patients With Castration-Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patient Inclusion : Patient may M0 M1 disease Confirmed diagnosis CRPC define Testosterone castrate level , evidence serum testosterone level ≤ 1.73 nmol/L ( 50 ng/dL ) Clear progressive disease , evidence minimum two rise PSA level measure least 7 day apart new clinical imaging evidence progressive metastatic disease Initiating first second line treatment CRPC : include anti androgen , androgen synthesis inhibitor , chemotherapy , immunotherapy radionuclide therapy . Previous first line CRPC treatment limit : First generation antiandrogens ( bicalutamide , flutamide , nilutamide ) SipuleucelT Patients may enrol within 90 day time decision treat within 90 day treatment initiation . Willing able complete periodic patientreported outcome ( PRO ) questionnaires , without assistance Estimated life expectancy ≥ 6 month Caregiver Inclusion : Meets definition unpaid relative friend help patient activity daily live Willing able complete caregiverreported outcome questionnaire course patient 's participation study Patient Exclusion : Receiving concomitant treatment cancer ( exclude basal cell carcinoma , squamous cell carcinoma treatment hormone sensitive prostate cancer ) within 6 month prior enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castration-resistant Prostate Cancer</keyword>
	<keyword>Metastatic Prostate Cancer</keyword>
</DOC>